Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025571 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025571: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT00025571 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025571, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have non-small cell lung cancer.
Interventions
- DRUG HPPH
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
What the finished NCT00025571 record still lists
NCT00025571 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which HPPH is the first listed.
NCT00025571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025571 about?
NCT00025571 is a clinical study titled "Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectivene...
What is the current status of trial NCT00025571?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00025571?
The interventions under investigation include: HPPH (DRUG).
Who is sponsoring clinical trial NCT00025571?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia